Results 11 to 20 of about 112,698 (266)

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Haematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Readelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, Rocco Piazza   +27 more
doaj   +1 more source

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

Haematologica, 2008
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara, Rossana Maffei, Silvia Martinelli, Annalisa Arcari, Federico Piacentini, Elena Trabacchi, Pierluigi Alfieri, Angela Ferrari, Giovanna Leonardi, Gabriele Luppi, Giuseppe Longo, Daniele Vallisa, Roberto Marasca, Giuseppe Torelli   +13 more
doaj   +1 more source

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Journal of Medical Case Reports, 2011
Introduction In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions.
Scheid Christoph, Kochanek Matthias, Nogova Lucia, Rothe Achim, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael   +5 more
doaj   +1 more source

Report of an Unusual Case: Testicular Involvement of Chronic Myeloid Leukemia 10 Years after the Complete Response [PDF]

Journal of Clinical and Diagnostic Research, 2014
Testicular extra-medullary myeloid cell tumours are rare tumours presenting in most cases with painless testicular swelling. We present here a case of 21-year-old man with painless scrotal swelling.
Cem Nedim Yuceturk, Berat Cem Ozgur, Hasmet Sarici, Pelin Borcek, Onur Telli   +4 more
doaj   +1 more source

A Case of Chronic Myeloid Leukemia Presenting with Osteoid Osteoma: A Diagnostic Dilemma

Asian Pacific Journal of Cancer Care, 2021
Chronic myeloid leukemia is a hematological malignancy resulting from a clonal proliferation of hematopoietic stem cells of the myeloid series. It is developed by chromosomal translocation.
Mannavi Suman, Anis Bandyopadhyay, Arnab Kumar Ghosh, Sk Rahamatulla, Alakananda Choudhury   +4 more
doaj   +1 more source

Comparative analysis of blood lymphocytes of patients with acute and chronic myeloid leukemia by surface and intracellular α1-acid glycoprotein and fibronectin

Біологічні студії, 2014
The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj   +1 more source

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

Haematologica, 2010
Background Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib.
Fabrizio Vianello, Federica Villanova, Veronica Tisato, Stefania Lymperi, Ka-Kei Ho, Ana R. Gomes, David Marin, Dominique Bonnet, Jane Apperley, Eric W.-F. Lam, Francesco Dazzi   +10 more
doaj   +1 more source

Bosutinib for Chronic Myeloid Leukemia [PDF]

Rare Cancers and Therapy, 2015
In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option.
Breccia, Massimo, Binotto, Gianni
openaire   +2 more sources

Bilateral vision loss as initial presentation of chronic myeloid leukemia in a young adult: A case report and review of the literature

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case of bilateral vision loss as the primary presenting symptom of chronic myeloid leukemia in a young adult. Observations: The 28-year-old male patient presented to clinic with visual acuity of 20/200 in both eyes after several ...
Nathan J. Brown, Erin A. Kaya, Jonathan G. Haymore, Lauren V. Gioia   +3 more
doaj   +1 more source

A prisoner with chronic myeloid leukemia [PDF]

Bone Marrow Transplantation, 1999
The health care received by prisoners in the area of tissue and organ transplantation is not well discussed or documented. We encountered a prisoner with newly diagnosed chronic myelogenous leukemia who was a candidate for allogeneic bone marrow transplantation and had two HLA-identical siblings who were willing to donate bone marrow.
R, Navari, J, Horner Catt, M, Siegler
openaire   +2 more sources